Acumen Pharmaceuticals (ABOS) Share-based Compensation (2020 - 2026)

Acumen Pharmaceuticals has reported Share-based Compensation for 7 years, with the latest figure at $2.4 million in Q1 2026.

• Quarterly Share-based Compensation rose 3182.19% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 66.83% YoY) and the FY2025 annual result came in at $73000.0, down 99.24% from the prior year.
• Share-based Compensation rose to $2.4 million in Q1 2026 per ABOS's latest filing, from -$4.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $7.3 million in Q3 2024 and troughed at -$4.9 million in Q3 2025.
• A 5-year average of $1.5 million and a median of $2.4 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation slumped 403.15% in 2022, then soared 3182.19% in 2026.
• Over 5 years, Share-based Compensation stood at $2.8 million in 2022, then soared by 117.29% to $6.1 million in 2023, then plunged by 61.87% to $2.3 million in 2024, then plunged by 309.09% to -$4.9 million in 2025, then jumped by 148.91% to $2.4 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2.4 million, -$4.9 million, and $4.9 million for Q1 2026, Q3 2025, and Q2 2025 respectively.